Introduction
Parkinson's disease (PD) is a major progressive neurodegenerative disorder characterized by a loss of the dopamine (DA) neurons in the nigrostriatal circuitry governing the control of muscle movement [1] . The decrease in dopaminergic (DA-ergic) tone results in a disturbed balance in the neural circuitry of the basal ganglia [2] resulting in symptoms like akinesia, bradykinesia, rigidity, resting tremor and postural instability. Current pharmacological strategies are focussed on increasing DA-ergic neurotransmission using DA receptor agonists and l-dihydroxy-phenylalanine (l-DOPA). These compounds are still the most effective, although long term medication causes complications such as motor fluctuations and dyskinesia [3, 4] . To overcome these side effects related to direct intervention in the DA system, Non-DA-ergic strategies using compounds that modulate indirectly the DA system would be a good alternative and/or supplement to the DA replacement therapies [5] . Indeed, the pathology is not only restricted to the substantia nigra of the basal ganglia and DA-ergic system, as the noradrenergic (NE), cholinergic and serotonergic systems are also affected [6] . Accordingly, the NE system, which finds its main origin in the Locus Coeruleus (LC) plays a pivotal role in the in the regulation of the nigrostriatal DA pathways [7] . Alpha2C adrenergic subtype receptors are of particular interest as it is part of a negative feedback loop to regulate NE release and therefore DA neurotransmission. Functionally, numerous selective alpha2-adrenoceptor modulators have been developed and proposed to provide an effective treatment in PD [8] [9] [10] .
Recently we have developed a selective alpha2C adrenergic antagonist JNJ27063699 with high oral availability and metabolic stability. The half-life for rat is 3.7 h and for dogs 6.8 h. The oral absorption is very good: the bioavailability measured in three different species is 30-40%. JNJ27063699 displays a high in vitro potency and subnanomolar affinity (Ki = 0.28 nM) for the h-alpha2C adrenoreceptor with high selectivity over the human alpha2A-and alpha2B-adrenoceptor subtypes as well as over the alpha1A-receptor, while in vitro profiling across a wide range of other binding assays showed no activity (CEREP data on file). The maximum selected dose (10 mg/kg p.o.) resulted in >80% brain receptor binding in rats, measured 2 h after dosing. The present studies aimed at investigating the potency of JNJ27063699, in three consecutive sequential doses, to alleviate the parkinsonian symptoms and improve the motor deficits in the MPTP marmoset model of idiopathic PD. The MPTP challenge in non-human primates causes specific intoxication of DA-ergic structures and loss of nigrostriatal DA neurons leading to long-lasting motor and non-motor impairments characteristic and neuropathological features similar to PD in humans, which makes the MPTP marmoset model an essential tool suitable for translational studies in PD [11] [12] [13] [14] [15] . An advantage of the marmoset monkey is the availability of automated test systems for measuring motor deterioration in a quantitative manner. In human neurodegenerative diseases such as PD, spontaneous activity levels are greatly affected. In marmoset monkeys, a device/set up called the 'Bungalow' has been developed quantifying the spontaneous locomotor activity [16] . Furthermore, the fine motor skills of patients are reduced due to a combination of tremor, slowness of movement and disturbed motor planning. Indeed, assessment of these fine motor skills in MPTP non-human primates, e.g. hand-eye coordination is also affected [17] . The hand-eye coordination task according to Wolthuis et al. [18] proved to be very suitable for PD studies [19] . Both test systems were extensively validated in the MPTP marmoset model [15, [19] [20] [21] [22] .
Methods

Animals
Twelve adult common marmoset monkeys (Callithrix jacchus) of both sexes between five and seven years of age and body weights between 300 and 450 g were obtained from the German Primate Centre (DPZ), Germany and the Biomedical Primate Research Centre (BPRC), The Netherlands. These animals were equally subdivided over two treatment groups (n = 6 per group). They were housed under controlled temperature (25 ± 2 • C), humidity (>60%) and standard 12:12 light cycle regime (lights on from 7:00 a.m. to 7:00 p.m., illumination intensity: ∼650 lx). The monkeys were daily fed with standard monkey-chow (SSNIFF and SDSS) enriched with fruit and vegetables of the season. Water was available at libitum. All animal procedures were approved by local laws and are in line with European Community guidelines. Protocols were reviewed by the local Ethical Review Committee on Experimental Animals, prior to the start of experiments.
Drug administration
The vehicle, for oral administration of the test compounds, consisted of water: strawberry syrup in a 2:1 proportion and was administered orally (po) in a dose of 1 ml/kg. The test compound JNJ27063699 obtained from Janssen Research and Development was dissolved in the vehicle, as mentioned above, in the following concentrations: 0.1 mg/kg for low dose, 1 mg/kg for middle dose and 10 mg/kg for high dose. MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride; Sigma Chemical Co., St. Louis, USA) was injected subcutaneous (sc) in the abdominal area for three consecutive days (respectively 2.0, 1.5, and 1.0 mg/kg), and continued after a 2-day rest period for another two consecutive days of MPTP injections (both at 1.5 mg/kg) to induce a moderate state of PD.
Experimental design
For the validation of the anti-Parkinson efficacy behavioural assays were used: Observational symptoms assessing parkinsonian features as immobility, apathy, rigidity, and tremors were analysed, while motor deterioration was assessed by analysis of the locomotor activity and complex motor behaviour.
Side effects of the treatments on the assays used were investigated in a separate group, in which the animals received saline-injections instead of MPTP during the disease induction.
All monkeys were trained on the hand-eye coordination task and baseline values of all test systems used were obtained before the start of the experiments. Based on hand-eye coordination performance, locomotor activity in the bungalow task, age and gender, the monkeys were stratified into two equal test groups. One group (n = 6) received five MPTP injections within a week time period till stable moderate parkinsonian symptoms were established (total MPTP dose: 7.5 mg/kg). The other group (n = 6) received time and volume-matched subcutaneous administration of saline.
After disease stabilization of two weeks, the effects of oral administration of vehicle and of JNJ27063699 (0.1, 1 and 10 mg/kg) were evaluated with a week time interval, respectively (n = 6 for each dose). A wash out period of one week was observed between each experiment. An observational scoring scale for clinical parkinsonian signs, behavioural assays (hand-eye coordination and locomotor activity), body weight and body temperature were used to test the efficacy of JNJ27063699. The observational parameters, body weight and body temperature were scored one day before administration, the morning before administration, 50 min after administration and one day after administration. The efficacy on both the hand-eye coordination and the locomotor activity were measured at 60 and 75 min after administration of the compounds, respectively.
Physical signs
Clinical assessment of PD symptoms in the clinic is mostly done with the Unified Parkinson's Disease Rating Scale (UPDRS). Here, we used a clinical rating scale to score cardinal parkinsonian symptoms in marmosets such as (a) inadequacy of grooming by inspection of the fur; (b) apathy by testing the responsiveness of the animal to its surrounding; (c) immobility; (d) rigidity; and (e) presence of tremors. All items were rated from 0 to 4: 0 (not observed), 1 (normal), 2 (mild), 3 (moderate), and 4 (severe). The observations were performed in a blinded manner. In addition, both body weight and temperature were simultaneously measured to provide additional indices of clinical state of the animal and side effects.
Bungalow task for locomotor activity
An automated activity test was used to quantify locomotor behaviour [16, 19] , which has shown its validity in the MPTP treated marmoset monkey [15] . The device resembles a 4-room bungalow of horizontally placed non-transparent compartments (23 cm × 23 cm × 23 cm), covered with a wire mesh top. All compartments were interconnected by six PVC tubes (Ø 9.5 cm). The tubes are designed to allow the animal to move directly to one of the three other compartments. The monkeys were familiarized with the bungalow system one week prior to the baseline recordings. A video tracking system (Ethovision, Noldus, The Netherlands) registered the loco-motor activity of the animal, expressed as the number of compartment changes during 20-min sessions.
Hand-eye coordination task
Fine motor skills of patients are reduced due to a combination of tremor, slowness of movement and disturbed motor planning. Comparable fine motor skills, e.g. hand-eye coordination, in MPTP non-human primates, are also affected (reviewed by Emborg [17] ). The robot-guided hand-eye coordination task according to Wolthuis et al. [18] was proved to be very suitable for PD studies [15, 19] . In brief, the marmoset was placed in front of the test panel containing a window (8 cm × 5 cm) that is provided with a vertically sliding door. Behind the window, a robot arm presented 42 marshmallow-like rewards, passing at different rates: non-moving (0.0 m/s for a maximum of 30 s); slow moving (0.04 m/s); and fast moving (0.08 m/s). Each test session consisted of 14 trials at each rate. A brief sound signal was used to alert the monkey before each trial and in between each trial the window was closed by a sliding door. The number of correctly taken rewards was used as a criterion to judge the performance of the marmoset monkey. Before start of the study, all monkeys were trained to grasp >33 out of the 42 presented rewards.
Statistics
SPSS (Statistical Package for Social Sciences, version 15.0, SPSS (SPSS Inc, Chicago, USA) was used for all data analyses with repeated measures ANOVA per measured variable (time and treatment effect). All data expressed as mean ± SEM were submitted to post-hoc paired t-test, in which each animal served as its own control. A value of p < 0.05 was considered to be significant.
Results
Side effects of the JNJ27063699 in healthy monkeys
Clinical parkinsonian symptoms
Under normal healthy condition, JNJ27063699 has no significant effects on the clinical parkinsonian scores at any tested dose and any time point (not shown). Repeated measures ANOVA reveals an overall effect of treatment at one day after administration (24 h) compared to 1 h before administration (−1 h) and an overall change for the basal values at the preceding days. However, paired t-tests revealed no significances for any of the treatments at one hour (1 h) or 24 hours (24 h) after administration as compared to 1 h before administration (−1 h) and the values one day before administration (−24 h) at treatment days were not significantly different from these values of the vehicle test day (paired t-tests).
Body weight and temperature
Before the start of the first saline injection the average body weight was 393.8 ± 8.5 g and at the end of the study it was 387.2 ± 8.5 g. The body weights of healthy saline-pretreated animals before and after treatment showed no significant overall effects of treatment or differences per treatment between test-(24 h) and preceding values (−24 h) (repeated measures ANOVA and paired t-tests) (data not shown).
There was also no significant change in body temperature of the healthy saline-pretreated monkeys after treatment (data not shown). No significant overall differences on body temperature between 1 h before (−1 h) and 1 h after (1 h) or one day after (24 h) administration, no overall effects of treatment or interactions between these were found (repeated measures ANOVA).
Locomotor activity
In the healthy saline-pretreated monkeys a significant overall effect of treatment on the locomotor activity was found (see Fig. 1 ; repeated measures ANOVA, F(6,30) = 14.56; p < 0.001). Statistical analysis using paired t-tests showed that JNJ27063699 at highest dose of 10 mg/kg significantly increased the number of compartment changes compared to their baseline value before saline administration (t(5) = −5.49; p < 0.01), but not compared to vehicle oral administration and after the saline injections (p > 0.05).
Hand-eye coordination
In the healthy saline-pretreated monkeys no significant differences were found between the different treatment regimens on the performance in the hand-eye coordination task (not shown). The mean baseline level on the performance was 37.7 ± 0.9 number of correctly taken rewards. After the saline injections the performance score was 31.8 ± 3.7 number of correctly taken rewards. JNJ27063699 did not affect the performance (0.1 mg/kg: 39.5 ± 1.6; 1 mg/kg: 36.0 ± 3.7; 10 mg/kg: 37.2 ± 2.0 correctly taken rewards). Repeated measures ANOVA revealed a significant overall treatment effect (F(6,30) = 3.59; p < 0.01). However, paired t-tests showed no significant effects between any treatments compared to the saline treatment.
Anti-Parkinson effects of JNJ27063699
Clinical parkinsonian symptoms
MPTP-pretreatment affected the clinical parkinsonian score in a progressive gradual way to a cumulative average score of 15 Efficacy of JNJ27063699 was tested 1 h and 24 h after administration. No significant differences were found between '−24 h' and '1 h', and between '−24 h' and '24 h' for any of the treatments (repeated measures ANOVA and paired t-tests). No significant trend was found for the basal values at the preceding days (repeated measures ANOVA), and '−24 h' values at JNJ treatment days were not significantly different from the '−24 h' values of the vehicle test day (paired t-tests). In the vehicle treated monkeys, no significant sign of recovery of total clinical score in time was found indicating a stable parkinsonian state during the drug test period, also no significant effects of the JNJ treatment was found on the total clinical parkinsonian score. "Appetite" was not scored 1 h after treatment, and therefore this parameter was extracted before statistical analysis of treatment effect at '1 h' after administration.
Body weight and temperature
During PD induction with MPTP no changes were found on both body weight and body temperature. After treatment with the different dosages of the JNJ27063699, the body weight of the MPTPpretreated monkeys was not affected (not shown). The average body weight before the first MPTP treatment was 357.3 ± 12.7 g and at the end of the study it was 327.3 ± 17.8 g; an average decline of 30 g compared to 6 g in the saline treatment. Repeated measures ANOVAs showed no significant overall differences between '−24 h' and '24 h', no overall effect of treatment or an interaction between these.
There was also no significant change in body temperature on the preceding (−24 h) days (repeated measures ANOVA) (data not shown). No significant overall differences between '−1 h' and '1 h' and between '−1 h' and '24 h' measures, no overall effects of treatment or interactions between these were found (repeated measures ANOVA).
Locomotor activity
Baseline explorative locomotor activity in the untreated monkeys was measured two times before MPTP or saline injections. Data from the second test session were used as the baseline value, represented in Fig. 3 . The mean basal activity was about 40 compartment changes during a 20-min session. Two days after the last MPTP injection the locomotor activity was significantly affected (Fig. 3) : the activity declined from about 40 compartment changes to almost zero changes within the 20-min registration period (paired t-test, *p < 0.05).
The activity in the bungalow task was tested at predefined treatment days 75 min after treatment with vehicle, JNJ27063699 0.1, 1 and 10 mg/kg). The results of these tests were compared to the baseline values before MPTP treatment (baseline), and to the after-MPTP baseline values (MPTP induction), obtained two days after the last MPTP injection (Fig. 3) . The MPTP induction value (t(5) = 3.56; p < 0.05) and the value of the vehicle treatment after MPTP intoxication (t(5) = 3.88; p < 0.05) are significantly lower than the (pre-MPTP) baseline value (paired t-test). The low (t(5) = −3.74; p < 0.05), middle (t(5) = −3.10; p < 0.05) and high doses of JNJ27063699 (t(3) = −3.97; p < 0.05) show a significant increase in compartment changes compared to the MPTP induction value (repeated measures ANOVA followed by paired t-tests, p < 0.05), which indicate a beneficial effect with JNJ27063699 treatment.
Hand-eye coordination
After a training period of approximately five weeks (20 training sessions), the monkeys had reached a performance level of 37 ± 0.9 correctly taken rewards (baseline performance) on the hand-eye coordination task. The MPTP-treated marmoset monkeys showed a prominent and significant decrease of performance to 10.3 ± 1.8 correct responses (t(5) = 11.72; p < 0.001). The dose response effects of JNJ27063699 on the MPTP-induced decline in the hand-eye coordination task are shown in Fig. 4 . Repeated measures ANOVA revealed a significant overall treatment effect Fig. 3 . Mean (±SEM) compartment changes measured during weekly sessions in the "Bungalow task" in MPTP-pretreated marmoset monkeys (n = 6). The baseline bar represents the explorative activity of the monkeys before the start of MPTP treatment. The MPTP bar reflects the activity of the animals two days after the last MPTP injection. The middle and high doses of JNJ27063699 are represented by five animals. + indicates significant increased loco-motor activity compared to the MPTP-pretreatment (repeated measures ANOVA followed by paired t-tests, p < 0.05). * indicates significant difference from baseline values (paired t-test, p < 0.05). (F(6,18) = 4.47; p < 0.01). The JNJ27063699 compound could not significantly improve the performance compared to the MPTP induction value (paired t-test, + p < 0.05). Nevertheless, after MPTP, with vehicle and lowest dose of JNJ treatment a significantly less performance was found compared to the baseline value (repeated measures ANOVA followed by paired t-tests, *p < 0.05). This significant decline in performance was not found for the middle and high dose of JNJ27063699.
Discussion
Loss of the DA-ergic neurons by MPTP disturbs the balance in the basal ganglia resulting in an increased stimulation of the inhibitory projections from the globus pallidus interna (GPi)/substantia nigra reticula (SNR) to the motor nuclei outside the basal ganglia [2] . All these brain areas are involved in control, planning and execution of motor behaviour. The LC-noradrenergic system influences the functioning of the nigrostriatal DA system [23] . The maintainability of this function can be realized through pharmacological modulation of this system; specifically, with alpha2-adrenoceptor antagonists [7] . It is thought that alpha2C-adrenoceptor antagonists are indirectly related to DA release and interfere with the basal ganglia circuitry by evoking a significant decrease in GABA release [24] . The alpha2C-adrenergic receptor inhibits monoamine release in vitro brain slices and is presumably involved in the striatum inhibition of brain monoamine metabolism [25] . This, in combination with the fact that alpha2C-adrenoceptors occur in higher density in the striatum relative to other brain regions [24] , indicates that JNJ27063699 may affect the motor deteriorative effects induced by MPTP in a positive manner. Therefore, the putative efficacy of oral administration of the alpha2C-adrenoceptor antagonist JNJ27063699 to counteract the parkinsonian symptoms, motor coordination deficits and impaired locomotor activity was investigated in the MPTP marmoset model for PD. The MPTP marmoset model is a suitable model for testing the interaction of compensatory processes on the DA depletion because the MPTP PD induction protocol, used in this study, results in a decreased DA level in the corpus striatum from 5.47 ± 0.85 to 0.27 ± 0.08 g/g tissue (n = 6/group) measured 30 days after the last MPTP injection in a study with a similar induction protocol [15] . DA decline by MPTP treatment, according the described PD induction protocol, resulted in reduced locomotor activity, disturbed hand-eye coordination and induced PD-like symptoms in comparable studies [15, 21] . Similar effects on the read-out systems were found in the present study, which proved the face and external validity of the successful induction of PD. Statistical analysis of the scores on the days preceding the treatments showed that no significant spontaneous recovery of clinical scores, body weight or body temperature was measured over time, demonstrating that the disease model was stable during the study.
Under normal condition, in the control group (saline treated monkeys), blockade of alpha2C-adrenergic receptor did not yield to significant changes on any of the parameters on the selected assays, indicating that the doses used of JNJ27063699 did not lead to any aversive side effects on the test systems used. However, in parkinsonian monkeys, treatment with the sign-free doses of JNJ27063699 did improve complex motor skills of the hand-eye coordination to baseline level and restored explorative locomotor activity. Deterioration of the reach and grasp movements in PD is due to a loss of control over complex movements as the basal ganglia increases the speed and efficiency of cortical processing [26] . The most effective PD-medication l-DOPA is not able to improve some aspects of skilled movements in human PD patients and parkinsonian rodents [27, 28] . This may indicate that restoration of this executive function of the basal ganglia needs a specialized targeting probably involving the NE system. Since the same dose of JNJ27063699 given to naive marmosets did not change the hand-eye coordination, indicates that the basal ganglia system after MPTP intoxication becomes more sensitive for the modulatory actions of JNJ27063699.
The improved locomotor activity is presumably due to arousal effects. A low arousal state is a major factor in the inactivity of parkinsonian animals [15] . MPTP treated non-human primates have a low arousal state and narcolepsy-like daytime naps [29] . The noradrenergic LC is one of the major wakefulness-promoting nuclei of the brain. It was shown, in a comparable PD study, that the wakefulness-promoting drug modafinil increases locomotor activity in parkinsonian marmoset monkeys generated by arousal effects [15] . The activity of the LC is believed to be tonical enhanced by a mesocoerulear DA-ergic pathway arising from the ventral tegmental area of the midbrain, which is indeed affected by modafinil [30] .
Although JNJ27063699 was able to mitigate motor dysfunction, it did not affect the parkinsonian clinical scores, including tremor. Tremors arise due to increased numbers of oscillatory and synchronous discharged neurons in MPTP-intoxicated monkeys in contrast to an uncorrelated neuronal discharge in the globus pallidus in normal primates [31] . The excessive thalamic-cortical connections of the direct pathway are responsible for the cortical motor system, akinesia, rigidity and tremor, whereas the inhibitory descending projection to brain-stem locomotor areas of the indirect pathway may contribute to gait and posture abnormalities [2, 32] . Based on the observed effects of JNJ27063699 on the motor-coordination and locomotor function, whereas the drug did not affect symptoms as rigidity and tremor, indicates that JNJ27063699 could act preferentially by activating the indirect motor pathway. Noteworthy, a similar response of unaffected clinical parkinsonian scores together with improvement on motor function was found with treatments based on NMDA antagonism [12] . NMDA antagonists modulate the indirect pathway [33] . Therefore, alpha2C-adrenoceptor antagonists, similar to NMDA antagonists, decrease the GABA release by the GPi/SNR resulting in excessive excitation of the thalamus, which results in activation of the cortical motor system. Then again, the NE system might affect more predominantly the indirect pathway.
In conclusion, the orally administered JNJ27063699 has beneficial effects on the alleviation of the parkinsonian motor symptoms: it restored motor activity to nearly pre-disease levels and the more complex hand-eye coordination task was improved, while clinical parkinsonian signs are still present. The exact mechanism of the NE system is still unknown, but it plays an important regulatory role within the indirect pathway to normalize the effects of the declined DA release. MPTP produces a widespread and severe reduction of not only DA but also of NE [7] . Indeed, a similar MPTP induction protocol as used in this study did result in a decline of the NE levels in the striatum from 0.49 ± 0.12 to 0.19 ± 0.04 g/g tissue [15] . Therefore intervention on the NE system in addition to the classical DA replacement regime might have potential in the treatment of PD. A multi-drug medication with an alpha2C-adrenoceptor antagonist may lower the dose of DA agonists postponing the occurrence of side effects of the current treatments.
